RNAi therapeutics: an antiviral strategy for human infections
AuthorKelleher, AD; Cortez-Jugo, C; Cavalieri, F; Qu, Y; Glanville, AR; Caruso, F; Symonds, G; Ahlenstiel, CL
Source TitleCurrent Opinion in Pharmacology
University of Melbourne Author/sCaruso, Francesco; Cortez-Jugo, Christina; Cavalieri, Francesca; Qu, Yijiao
AffiliationChemical and Biomolecular Engineering
Document TypeJournal Article
CitationsKelleher, A. D., Cortez-Jugo, C., Cavalieri, F., Qu, Y., Glanville, A. R., Caruso, F., Symonds, G. & Ahlenstiel, C. L. (2020). RNAi therapeutics: an antiviral strategy for human infections. Current Opinion in Pharmacology, 54, pp.121-129. https://doi.org/10.1016/j.coph.2020.09.011.
Access StatusOpen Access
Open Access URLhttps://doi.org/10.1016/j.coph.2020.09.011
Gene silencing induced by RNAi represents a promising antiviral development strategy. This review will summarise the current state of RNAi therapeutics for treating acute and chronic human virus infections. The gene silencing pathways exploited by RNAi therapeutics will be described and include both classic RNAi, inducing cytoplasmic mRNA degradation post-transcription and novel RNAi, mediating epigenetic modifications at the transcription level in the nucleus. Finally, the challenge of delivering gene modifications via RNAi will be discussed, along with the unique characteristics of respiratory versus systemic administration routes to highlight recent advances and future potential of RNAi antiviral treatment strategies.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References